Welcoming Board Member, Sunit Rikhi

Sunit Rikhi is a semiconductor industry executive with over thirty five years of experience. In May 2015, Sunit retired from a 30 year career with Intel as Vice President and General Manager of Intel Custom Foundry. In 2008, he started this business unit from scratch to provide leading edge custom silicon manufacturing services to fabless design companies. At the time he left Intel, the business unit had over a thousand engineers spread across the globe and on a path to ramping volume to over a billion dollars of revenue run rate from over ten customers in the USA and Asia.Between 2002 and 2008, Sunit successfully led the synchronization of advanced designs with Moore’s Law nodes from 65 nanometers (nm) down to 22nm. During this time, Sunit led Intel’s Design-For-Manufacturing initiative and gave shape to a brand new engineering discipline called computational lithography.  From 1994 to 2002, Sunit led the semiconductor industry in revolutionizing manufacturing operations with fully automated 300 millimeters silicon wafer manufacturing factories. Under his leadership, an entire industrial automation system was put in place to establish the gold standard for not only Intel’s global factory network, but also that of the world.  Prior to 1994, Sunit made several engineering management contributions to Intel’s Mask Shop, Intel’s Design Automation, American Microsystems’ Design Automation and Boeing’s 757 program.Sunit is a graduate of University of Washington (MSEE) and Birla Institute of Technology and Science (BSEE). Sunit’s focus as board member of cc-TDI:   As member of cc-TDI Executive Board of Directors, Sunit will help the company establish an organizational culture with engineering discipline and results orientation. He will also facilitate the company’s engagement with engineering talent available in the greater Portland area to give shape to our strong belief that new therapies for children’s cancer can be brought to market faster by infusing innovative engineering approaches into bio-medical research and development.